<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01282164</url>
  </required_header>
  <id_info>
    <org_study_id>10-810</org_study_id>
    <nct_id>NCT01282164</nct_id>
  </id_info>
  <brief_title>The Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and Adrenocorticotropic Axis</brief_title>
  <acronym>GST</acronym>
  <official_title>The Diagnostic Accuracy of the Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and the Hypothalamic-Pituitary-Adrenal Axis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Allegheny Endocrinology Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if the Glucagon Stimulation Test (GST) is a reliable
      alternative to the Insulin Tolerance Test (ITT) for diagnosis of Growth Hormone Deficiency
      (GHD) and adrenal insufficiency. In some patients the accuracy of the GST for evaluation of
      adrenal insufficiency is compared to the adrenocorticotropin hormone (ACTH ) stimulation
      test.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Growth hormone is a protein that is produced by the pituitary gland and influences the
      metabolism (how fast things work) of other proteins, carbohydrates, and fats in the body.
      This allows the growth hormone to help humans keep a healthy balance between fat, muscle and
      bone throughout their life. Some people have what is called Growth Hormone Deficiency (GHD),
      which means that they do not produce enough growth hormone. GHD may lead to a tendency to be
      fat, (especially around the abdominal area), a reduced ability to exercise, heart disease, an
      increased possibility of breaking bones, and a general reduced quality of life.

      GHD is usually evaluated through growth hormone stimulation test(s). One of the most reliable
      tests to evaluate if someone has GHD is by using arginine + Growth Hormone Releasing Hormone
      (GHRH) test. However, Since 2008 GHRH is no longer available in the USA. For this reason
      there has been a significant gap for an alternative test for evaluation of patients suspected
      to have GHD that can be easily performed and be reliable. The Insulin Tolerance Test (ITT) is
      generally considered the gold standard test for evaluation of growth hormone (GH) deficiency.
      The ITT involves giving insulin intravenously (through a plastic tube inserted in your vein)
      to lower your blood sugar followed by the collection of blood samples to evaluate how your
      body handles low blood sugar. There are side effects of the ITT including hypoglycemia (low
      blood sugar causing you to become weak, perspire, shaky and have some mental cloudiness)
      which can be unpleasant. ITT can not be performed in patients older than 65 years of age and
      in those with certain medical conditions such as history of heart disease, seizure disorder
      or stroke. At the same time, the ITT needs to be done by an experienced clinician and
      requires trained staff to perform. For this reason there is a need for an alternative
      reliable test for evaluation of GHD.

      The second purpose of this study is to find out if you have adrenal insufficiency. Cortisol
      is a hormone produced by the adrenal gland and is released in response to stress. Cortisol
      production is regulated through the hypothalamus and the pituitary gland. Its primary
      functions are to increase blood sugar, regulate the immune system and aid in fat, protein and
      carbohydrate metabolism. Patients with low cortisol may experience fatigue, body ache, sleep
      disturbance, nausea and mood changes. Pituitary disorders may lead to low cortisol levels and
      can cause symptoms associated with adrenal insufficiency. The Insulin Tolerance Test (ITT)
      can also be used for the evaluation of adrenal function. Patients who can not undergo ITT,
      can be evaluated by the ACTH (adrenocorticotropic hormone) Stimulation Test, which is
      generally very well tolerated. Preliminary results from previous studies indicate that the
      Glucagon Stimulation Test (GST) may be used to evaluate adrenal function. The investigators
      in this study will compare your cortisol levels during two different GSTs with the cortisol
      levels achieved during ITT or ACTH stimulation test.

      Since the 1970s, the Glucagon Stimulation Test (GST) has been used by several research
      studies for evaluation of GHD and adrenal insufficiency. Glucagon is a hormone produced in
      the pancreas and is secreted during times of low blood sugar or in response to growth
      hormone. It is used to raise very low blood sugar and in diagnostic testing of the stomach
      and other digestive organs. Glucagon is readily available, relatively inexpensive and
      generally well tolerated; the major side effects include upset stomach that can lead to
      vomiting and headaches. It can be used in patients with diabetes and those older than 65
      years of age.

      The glucagon stimulation test (GST) has been suggested as an alternative test to ITT for
      evaluation of growth hormone deficiency (GHD) and adrenal insufficiency. The test is similar
      to the ITT and ACTH Stimulation Test in that blood samples are taken both before and after
      the medication is given. Glucagon is given intramuscularly (as in injection in your muscle).
      The fewer side effects make this an attractive substitute for the ITT. The 2007 consensus
      guideline by the GH Research Society considers GST as a test that may be used for evaluation
      of patients suspected to have GHD. However, the same statement does not provide any
      diagnostic cut-off value for GH during the GST. The purpose of this study is to see if the
      GST can be an accurate substitute for the ITT in the evaluation of both GHD and adrenal
      insufficiency.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak GH Level in Adult Patients With Hypothalamic-pituitary Disorders and 1-2 Pituitary Hormone Deficiency (PHD).</measure>
    <time_frame>one year</time_frame>
    <description>The peak growth hormone (GH) during Insulin Tolerance Test (ITT), fixed- dose glucagon stimulation test (GST) and weight-based GST in patients with adult onset hypothalamic-pituitary disease and 1-2 pituitary hormone deficiency (PHD) other than growth hormone (GH) deficiency.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Growth Hormone (GH) Level in Healthy Volunteers</measure>
    <time_frame>one year</time_frame>
    <description>The peak growth hormone (GH) during Insulin Tolerance Test (ITT), fixed- dose glucagon stimulation test (GST) and weight-based GST in healthy volunteers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak GH Level in Adult Patients With Hypothalamic-pituitary Disorders and Three or More Pituitary Hormone Deficiency (PHD).</measure>
    <time_frame>one year</time_frame>
    <description>The peak growth hormone (GH) during Insulin Tolerance Test (ITT), fixed- dose glucagon stimulation test (GST) and weight-based GST in patients with adult onset hypothalamic-pituitary disease with three or more pituitary hormone deficiency (PHD) other than growth hormone (GH) deficiency.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Cortisol Level in Adult Patients With Hypothalamic-pituitary Disorders and 1-2 Pituitary Hormone Deficiency (PHD).</measure>
    <time_frame>one year</time_frame>
    <description>The peak cortisol level during Insulin Tolerance Test (ITT), fixed- dose glucagon stimulation test (GST) and weight-based GST in patients with adult onset hypothalamic-pituitary disease and 1-2 pituitary hormone deficiency (PHD) other than growth hormone (GH) deficiency.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Cortisol Level in Healthy Volunteers.</measure>
    <time_frame>one year</time_frame>
    <description>The peak cortisol levels during Insulin Tolerance Test (ITT), fixed- dose glucagon stimulation test (GST) and weight-based GST in healthy volunteers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Cortisol Level in Adult Patients With Hypothalamic-pituitary Disorders and Three or More Pituitary Hormone Deficiency (PHD).</measure>
    <time_frame>one year</time_frame>
    <description>The peak cortisol level during Insulin Tolerance Test (ITT), fixed- dose glucagon stimulation test (GST) and weight-based GST in patients with adult onset hypothalamic-pituitary disease and three or more pituitary hormone deficiency (PHD) other than growth hormone (GH) deficiency.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Cortisol Level During Adrenocorticotropin Hormone (ACTH) Stimulation Test</measure>
    <time_frame>one year</time_frame>
    <description>The peak cortisol level during ACTH stimulation test in 3 patients with adult onset hypothalamic-pituitary disease who were older than 65 years of age and could not under go insulin tolerance test (ITT).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Adult Growth Hormone Deficiency</condition>
  <condition>Hypothalamic-pituitary Disorders</condition>
  <arm_group>
    <arm_group_label>Study patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients with growth hormone deficiency or hypothalamic-pituitary disorders underwent fixed-dose glucagon stimulation test (GST), weight-based GST and insulin tolerance test (ITT).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control group will consist of healthy volunteers matched to the study group for age, gender, Body mass index (BMI) and estrogen status. Note: Allegheny site is not enrolling in the control group.
Control subjects underwent fixed-dose glucagon stimulation test (GST), weight-based GST and insulin tolerance test (ITT).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Glucagon stimulation test and insulin tolerance test</intervention_name>
    <description>glucagon stimulation test using 1 mg (1.5 mg if weigh &gt;90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), cerebrovascular disease (CVD), seizure</description>
    <arm_group_label>Study patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>glucagon stimulation test and insulin tolerance test</intervention_name>
    <description>glucagon stimulation test using 1 mg (1.5 mg if weigh &gt;90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), CVD (cerebrovascular disease), seizure</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 80 years of age

          -  male and female

          -  hypothalamic pituitary disorders (study subjects)

          -  history of regular, age appropriate menses (control subjects)

          -  male subjects with normal serum testosterone and follicle stimulating hormone (FSH)
             (control subjects)

          -  normal FSH in post-menopausal subjects (control subjects)

          -  normal thyroid stimulating hormone (TSH), free thyroxine (T4), prolactin (control
             subjects)

        Exclusion Criteria:

          -  unable to give consent

          -  pregnancy

          -  active acromegaly

          -  pheochromocytoma

          -  active Cushing's disease

          -  pituitary insult within past 6 weeks

          -  elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST)

          -  renal failure

          -  history of malignancy

          -  severe acute illness

          -  uncontrolled hypertension

          -  Diabetes mellitus (DM) type 1

          -  Hemoglobin (Hgb) A1c &gt;9% in last 3 months in Type 2 DM

          -  severe coronary artery disease

          -  women &lt;50 years of age with untreated hypogonadism

          -  men with untreated hypogonadism

          -  growth hormone treatment in the past 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amir Hamrahian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Endocrinology, Diabetes and Metabolism</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Endocrinology Associates</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2011</study_first_submitted>
  <study_first_submitted_qc>January 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2011</study_first_posted>
  <results_first_submitted>December 27, 2016</results_first_submitted>
  <results_first_submitted_qc>February 20, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 5, 2017</results_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glucagon stimulation test</keyword>
  <keyword>insulin tolerance test</keyword>
  <keyword>growth hormone deficiency</keyword>
  <keyword>hypothalamic-pituitary disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary Diseases</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 28 patients with hypothalamic-pituitary disorders and 1â€“2 (n = 14) or 3 or more (n = 14) pituitary hormone efficiencies (PHD) were recruited from four pituitary centers.
A control group of 14 subjects was also recruited and underwent the insulin tolerance test (ITT) and the two glucagon stimulation tests (GSTs).</recruitment_details>
      <pre_assignment_details>There was no wash out period. Patients and controls were eligible for the study after the initial office visit for eligibility criteria, signing the consent form followed by labs to make sure that they are eligible for the study. One patient was excluded since the patient did not achieve hypoglycemia during insulin tolerance test</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Study Patients</title>
          <description>patients with growth hormone deficiency or hypothalamic-pituitary disorders
Glucagon stimulation test and insulin tolerance test: glucagon stimulation test using 1 mg (1.5 mg if weigh &gt;90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg adrenocorticotropin hormone (ACTH) stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), cerebrovascular disease (CVD), seizure</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>The control group will consist of healthy volunteers matched to the study group for age, gender, BMI and estrogen status. Note: Allegheny site is not enrolling in the control group.
glucagon stimulation test and insulin tolerance test: glucagon stimulation test using 1 mg (1.5 mg if weigh &gt;90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with T2DM, CAD, CVD, seizure</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of hypoglycemia during ITT</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One patient did not achieve hypoglycemia during the insulin tolerance test</population>
      <group_list>
        <group group_id="B1">
          <title>Study Patients</title>
          <description>patients with growth hormone deficiency or hypothalamic-pituitary disorders
Glucagon stimulation test and insulin tolerance test: glucagon stimulation test using 1 mg (1.5 mg if weigh &gt;90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with T2DM, CAD, CVD, seizure</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>The control group will consist of healthy volunteers matched to the study group for age, gender, BMI and estrogen status. Note: Allegheny site is not enrolling in the control group.
glucagon stimulation test and insulin tolerance test: glucagon stimulation test using 1 mg (1.5 mg if weigh &gt;90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with T2DM, CAD, CVD, seizure</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.0" spread="11.9"/>
                    <measurement group_id="B2" value="49.0" spread="12.2"/>
                    <measurement group_id="B3" value="50.3" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak GH Level in Adult Patients With Hypothalamic-pituitary Disorders and 1-2 Pituitary Hormone Deficiency (PHD).</title>
        <description>The peak growth hormone (GH) during Insulin Tolerance Test (ITT), fixed- dose glucagon stimulation test (GST) and weight-based GST in patients with adult onset hypothalamic-pituitary disease and 1-2 pituitary hormone deficiency (PHD) other than growth hormone (GH) deficiency.</description>
        <time_frame>one year</time_frame>
        <population>Peak GH levels during Insulin Tolerance test, fixed-dose GST and weight-based GST in Patients with hypothalamic-pituitary disorders and 1-2 pituitary hormone deficiency other than GH deficiency. One patient older than 65 years underwent adrenocorticotropin hormone (ACTH) stimulation test instead of ITT.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With 1-2 PHD- Insulin Tolerance Test</title>
            <description>Patients with hypothalamic-pituitary disorders and 1-2 pituitary hormone deficiency (PHD) other than GH deficiency
insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test was used in 3 subjects who were not eligible for ITT</description>
          </group>
          <group group_id="O2">
            <title>Patients With 1-2 PHD- Fixed Dose GST</title>
            <description>Patients with hypothalamic-pituitary disorders and 1-2 pituitary hormone deficiency (PHD) other than GH deficiency</description>
          </group>
          <group group_id="O3">
            <title>Patients With 1-2 PHD- Weight Based GST</title>
            <description>Patients with hypothalamic-pituitary disorders and 1-2 pituitary hormone deficiency (PHD) other than GH deficiency</description>
          </group>
        </group_list>
        <measure>
          <title>Peak GH Level in Adult Patients With Hypothalamic-pituitary Disorders and 1-2 Pituitary Hormone Deficiency (PHD).</title>
          <description>The peak growth hormone (GH) during Insulin Tolerance Test (ITT), fixed- dose glucagon stimulation test (GST) and weight-based GST in patients with adult onset hypothalamic-pituitary disease and 1-2 pituitary hormone deficiency (PHD) other than growth hormone (GH) deficiency.</description>
          <population>Peak GH levels during Insulin Tolerance test, fixed-dose GST and weight-based GST in Patients with hypothalamic-pituitary disorders and 1-2 pituitary hormone deficiency other than GH deficiency. One patient older than 65 years underwent adrenocorticotropin hormone (ACTH) stimulation test instead of ITT.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.2" upper_limit="18.8"/>
                    <measurement group_id="O2" value="0.6" lower_limit="0.1" upper_limit="6.9"/>
                    <measurement group_id="O3" value="0.7" lower_limit="0.1" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak Growth Hormone (GH) Level in Healthy Volunteers</title>
        <description>The peak growth hormone (GH) during Insulin Tolerance Test (ITT), fixed- dose glucagon stimulation test (GST) and weight-based GST in healthy volunteers</description>
        <time_frame>one year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group- ITT</title>
            <description>The control group consist of healthy volunteers matched to the study group for age, gender, BMI and estrogen status. Note: Allegheny site did not enroll the control group. All underwent insulin tolerance test using 0.10-0.15 U/kg</description>
          </group>
          <group group_id="O2">
            <title>Control Group- Fixed-dose GST</title>
            <description>The control group consist of healthy volunteers matched to the study group for age, gender, BMI and estrogen status. Note: Allegheny site is not enrolling in the control group.</description>
          </group>
          <group group_id="O3">
            <title>Control Group- Weight-based GST</title>
            <description>The control group consist of healthy volunteers matched to the study group for age, gender, BMI and estrogen status. Note: Allegheny site is not enrolling in the control group.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Growth Hormone (GH) Level in Healthy Volunteers</title>
          <description>The peak growth hormone (GH) during Insulin Tolerance Test (ITT), fixed- dose glucagon stimulation test (GST) and weight-based GST in healthy volunteers</description>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="2.5" upper_limit="42.7"/>
                    <measurement group_id="O2" value="4.5" lower_limit="1.3" upper_limit="11.3"/>
                    <measurement group_id="O3" value="5.8" lower_limit="2.3" upper_limit="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak GH Level in Adult Patients With Hypothalamic-pituitary Disorders and Three or More Pituitary Hormone Deficiency (PHD).</title>
        <description>The peak growth hormone (GH) during Insulin Tolerance Test (ITT), fixed- dose glucagon stimulation test (GST) and weight-based GST in patients with adult onset hypothalamic-pituitary disease with three or more pituitary hormone deficiency (PHD) other than growth hormone (GH) deficiency.</description>
        <time_frame>one year</time_frame>
        <population>Peak GH levels during Insulin Tolerance test, fixed-dose GST and weight-based GST in Patients with hypothalamic-pituitary disorders with three or more pituitary hormone deficiency other than GH deficiency. Two patients older than 65 years underwent adrenocorticotropin hormone (ACTH) stimulation test instead of ITT.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With 3 or More PHD- Insulin Tolerance Test</title>
            <description>Patients with hypothalamic-pituitary disorders and three or more pituitary hormone deficiency (PHD) other than GH deficiency
insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test was used in 3 subjects who were not eligible for ITT</description>
          </group>
          <group group_id="O2">
            <title>Patients With 3 or More PHD- Fixed Dose GST</title>
            <description>Patients with hypothalamic-pituitary disorders and three or more pituitary hormone deficiency (PHD) other than GH deficiency</description>
          </group>
          <group group_id="O3">
            <title>Patients With 3 or More PHD- Weight Based GST</title>
            <description>Patients with hypothalamic-pituitary disorders and three or more pituitary hormone deficiency (PHD) other than GH deficiency</description>
          </group>
        </group_list>
        <measure>
          <title>Peak GH Level in Adult Patients With Hypothalamic-pituitary Disorders and Three or More Pituitary Hormone Deficiency (PHD).</title>
          <description>The peak growth hormone (GH) during Insulin Tolerance Test (ITT), fixed- dose glucagon stimulation test (GST) and weight-based GST in patients with adult onset hypothalamic-pituitary disease with three or more pituitary hormone deficiency (PHD) other than growth hormone (GH) deficiency.</description>
          <population>Peak GH levels during Insulin Tolerance test, fixed-dose GST and weight-based GST in Patients with hypothalamic-pituitary disorders with three or more pituitary hormone deficiency other than GH deficiency. Two patients older than 65 years underwent adrenocorticotropin hormone (ACTH) stimulation test instead of ITT.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0.1" upper_limit="4.4"/>
                    <measurement group_id="O2" value="0.1" lower_limit="0.1" upper_limit="2.8"/>
                    <measurement group_id="O3" value="0.1" lower_limit="0.1" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak Cortisol Level in Adult Patients With Hypothalamic-pituitary Disorders and 1-2 Pituitary Hormone Deficiency (PHD).</title>
        <description>The peak cortisol level during Insulin Tolerance Test (ITT), fixed- dose glucagon stimulation test (GST) and weight-based GST in patients with adult onset hypothalamic-pituitary disease and 1-2 pituitary hormone deficiency (PHD) other than growth hormone (GH) deficiency.</description>
        <time_frame>one year</time_frame>
        <population>Peak cortisol levels during Insulin Tolerance test, fixed-dose GST and weight-based GST in Patients with hypothalamic-pituitary disorders and 1-2 pituitary hormone deficiency other than GH deficiency. One patient older than 65 years of age underwent ACTH stimulation test instead of ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With 1-2 PHD- Insulin Tolerance Test</title>
            <description>Patients with hypothalamic-pituitary disorders and 1-2 pituitary hormone deficiency (PHD) other than GH deficiency
insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test was used in 3 subjects who were not eligible for ITT</description>
          </group>
          <group group_id="O2">
            <title>Patients With 1-2 PHD- Fixed Dose GST</title>
            <description>Patients with hypothalamic-pituitary disorders and 1-2 pituitary hormone deficiency (PHD) other than GH deficiency</description>
          </group>
          <group group_id="O3">
            <title>Patients With 1-2 PHD- Weight Based GST</title>
            <description>Patients with hypothalamic-pituitary disorders and 1-2 pituitary hormone deficiency (PHD) other than GH deficiency</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Cortisol Level in Adult Patients With Hypothalamic-pituitary Disorders and 1-2 Pituitary Hormone Deficiency (PHD).</title>
          <description>The peak cortisol level during Insulin Tolerance Test (ITT), fixed- dose glucagon stimulation test (GST) and weight-based GST in patients with adult onset hypothalamic-pituitary disease and 1-2 pituitary hormone deficiency (PHD) other than growth hormone (GH) deficiency.</description>
          <population>Peak cortisol levels during Insulin Tolerance test, fixed-dose GST and weight-based GST in Patients with hypothalamic-pituitary disorders and 1-2 pituitary hormone deficiency other than GH deficiency. One patient older than 65 years of age underwent ACTH stimulation test instead of ITT</population>
          <units>ug/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" lower_limit="18.6" upper_limit="29.3"/>
                    <measurement group_id="O2" value="19.5" lower_limit="12.5" upper_limit="32.4"/>
                    <measurement group_id="O3" value="22.7" lower_limit="15.4" upper_limit="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak Cortisol Level in Healthy Volunteers.</title>
        <description>The peak cortisol levels during Insulin Tolerance Test (ITT), fixed- dose glucagon stimulation test (GST) and weight-based GST in healthy volunteers.</description>
        <time_frame>one year</time_frame>
        <population>Peak cortisol levels during Insulin Tolerance test, fixed-dose GST and weight-based GST in healthy volunteers</population>
        <group_list>
          <group group_id="O1">
            <title>Control Group- ITT</title>
            <description>The control group consist of healthy volunteers matched to the study group for age, gender, BMI and estrogen status. Note: Allegheny site did not enroll the control group. All underwent insulin tolerance test using 0.10-0.15 U/kg</description>
          </group>
          <group group_id="O2">
            <title>Control Group- Fixed-dose GST</title>
            <description>The control group consist of healthy volunteers matched to the study group for age, gender, BMI and estrogen status. Note: Allegheny site is not enrolling in the control group.</description>
          </group>
          <group group_id="O3">
            <title>Control Group- Weight-based GST</title>
            <description>The control group consist of healthy volunteers matched to the study group for age, gender, BMI and estrogen status. Note: Allegheny site is not enrolling in the control group.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Cortisol Level in Healthy Volunteers.</title>
          <description>The peak cortisol levels during Insulin Tolerance Test (ITT), fixed- dose glucagon stimulation test (GST) and weight-based GST in healthy volunteers.</description>
          <population>Peak cortisol levels during Insulin Tolerance test, fixed-dose GST and weight-based GST in healthy volunteers</population>
          <units>ug/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1" lower_limit="18.1" upper_limit="28.5"/>
                    <measurement group_id="O2" value="18.0" lower_limit="11.5" upper_limit="26.7"/>
                    <measurement group_id="O3" value="22.7" lower_limit="13.8" upper_limit="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak Cortisol Level in Adult Patients With Hypothalamic-pituitary Disorders and Three or More Pituitary Hormone Deficiency (PHD).</title>
        <description>The peak cortisol level during Insulin Tolerance Test (ITT), fixed- dose glucagon stimulation test (GST) and weight-based GST in patients with adult onset hypothalamic-pituitary disease and three or more pituitary hormone deficiency (PHD) other than growth hormone (GH) deficiency.</description>
        <time_frame>one year</time_frame>
        <population>Peak cortisol level during Insulin Tolerance test, fixed-dose GST and weight-based GST in Patients with hypothalamic-pituitary disorders with three or more pituitary hormone deficiency other than GH deficiency. Two patients older than 65 years of age underwent adrenocorticotropin hormone (ACTH) stimulation test instead of ITT.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With 3 or More PHD- Insulin Tolerance Test</title>
            <description>Patients with hypothalamic-pituitary disorders and three or more pituitary hormone deficiency (PHD) other than GH deficiency
insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test was used in 3 subjects who were not eligible for ITT</description>
          </group>
          <group group_id="O2">
            <title>Patients With 3 or More PHD- Fixed Dose GST</title>
            <description>Patients with hypothalamic-pituitary disorders and three or more pituitary hormone deficiency (PHD) other than GH deficiency</description>
          </group>
          <group group_id="O3">
            <title>Patients With 3 or More PHD- Weight Based GST</title>
            <description>Patients with hypothalamic-pituitary disorders and three or more pituitary hormone deficiency (PHD) other than GH deficiency</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Cortisol Level in Adult Patients With Hypothalamic-pituitary Disorders and Three or More Pituitary Hormone Deficiency (PHD).</title>
          <description>The peak cortisol level during Insulin Tolerance Test (ITT), fixed- dose glucagon stimulation test (GST) and weight-based GST in patients with adult onset hypothalamic-pituitary disease and three or more pituitary hormone deficiency (PHD) other than growth hormone (GH) deficiency.</description>
          <population>Peak cortisol level during Insulin Tolerance test, fixed-dose GST and weight-based GST in Patients with hypothalamic-pituitary disorders with three or more pituitary hormone deficiency other than GH deficiency. Two patients older than 65 years of age underwent adrenocorticotropin hormone (ACTH) stimulation test instead of ITT.</population>
          <units>ug/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="1.0" upper_limit="18.0"/>
                    <measurement group_id="O2" value="2.3" lower_limit="1.0" upper_limit="16.9"/>
                    <measurement group_id="O3" value="2.5" lower_limit="1.0" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Peak Cortisol Level During Adrenocorticotropin Hormone (ACTH) Stimulation Test</title>
        <description>The peak cortisol level during ACTH stimulation test in 3 patients with adult onset hypothalamic-pituitary disease who were older than 65 years of age and could not under go insulin tolerance test (ITT).</description>
        <time_frame>one year</time_frame>
        <population>Peak cortisol level during ACTH stimulation test in three patients with hypothalamic-pituitary disorders who were older than 65 and could not undergo ITT based on the study protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Older Than 65</title>
            <description>Three patients with adult onset hypothalamic-pituitary disease underwent who were older than 65 years of age underwent ACTH stimulation test instead of ITT.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Cortisol Level During Adrenocorticotropin Hormone (ACTH) Stimulation Test</title>
          <description>The peak cortisol level during ACTH stimulation test in 3 patients with adult onset hypothalamic-pituitary disease who were older than 65 years of age and could not under go insulin tolerance test (ITT).</description>
          <population>Peak cortisol level during ACTH stimulation test in three patients with hypothalamic-pituitary disorders who were older than 65 and could not undergo ITT based on the study protocol</population>
          <units>ug/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="1.2" upper_limit="23.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <desc>Observation during dynamic testing and follow up telephone call</desc>
      <group_list>
        <group group_id="E1">
          <title>Study Patients</title>
          <description>patients with hypothalamic-pituitary disorders
Glucagon stimulation test and insulin tolerance test: glucagon stimulation test using 1 mg (1.5 mg if weigh &gt;90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with T2DM, CAD, CVD, seizure</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>The control group will consist of healthy volunteers matched to the study group for age, gender, BMI and estrogen status. Note: Allegheny site is not enrolling in the control group.
glucagon stimulation test and insulin tolerance test: glucagon stimulation test using 1 mg (1.5 mg if weigh &gt;90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with T2DM, CAD, CVD, seizure</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="28"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This includes the relatively small number of subjects, and that the majority of patients had growth hormone deficiency (GHD), so a larger study assessing adults with mild hypothalamic-pituitary disease and possible but unconfirmed GHD is required.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Amir H. Hamrahian</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216-445-8555</phone>
      <email>hamraha@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

